La Jolla Pharmaceutical Company (PINK: LJPC), a biopharmaceutical company engaged in the development of treatments that significantly improve outcomes in patients with life-threatening diseases, announced that it completed the acquisition of global development and commercial rights to GCS-100 from Solona Therapeutics Inc.
GCS-100 is a novel therapeutic. It is a first-in-class inhibitor of galectin-3, which is a novel molecular target implicated in cancer and chronic organ failure.
In relation with the acquisition of GCS-100, George F. Tidmarsh, M.D., Ph. D., who is the former CEO of Solona, has been appointed as LJPC’s President and CEO. Tidmarsh has more than 20 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs.
Tidmarsh said that having been involved in the clinical development of GCS-100 over the past several years, he is thrilled to have the opportunity to continue the compound’s development in the context of LJPC. Tidmarsh also said that targeting galectin-3 holds great promise in the treatment of a broad range of life-threatening conditions, and, with GCS-100, LJPC has the most advanced galectin-3-targeting compound in development.
In connection with the acquisition, the company has also appointed Saiid Zarrabian as an independent director of the company. Also, the former members of management team at LJPC, including Deirdre Y. Gillespie, and Gail A. Sloan, have resigned.
Galectin-3 plays a significant role in the immune system’s response to cancer and tissue injury, which makes specific inhibitors of galectin-3 attractive therapeutic candidates for a wide range of life-threatening diseases such as cancer, heart failure, kidney disease, pulmonary fibrosis and liver fibrosis.
GCS-100’s continuing development as an anti-cancer and anti-fibrotic agent is backed by extensive preclinical and clinical investigation. Experimental results show that GCS-100 specifically inhibits galectin-3 in immune cells isolated from patients, confers anti-cancer activity in patients with several tumor types, exhibits effects on the immune system in patients consistent with its galectin-3 inhibitory mechanism and is safe and well-tolerated at doses that confer clinical activity.
GCS-100 is a novel therapeutic. It is a first-in-class inhibitor of galectin-3, which is a novel molecular target implicated in cancer and chronic organ failure.
In relation with the acquisition of GCS-100, George F. Tidmarsh, M.D., Ph. D., who is the former CEO of Solona, has been appointed as LJPC’s President and CEO. Tidmarsh has more than 20 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs.
Tidmarsh said that having been involved in the clinical development of GCS-100 over the past several years, he is thrilled to have the opportunity to continue the compound’s development in the context of LJPC. Tidmarsh also said that targeting galectin-3 holds great promise in the treatment of a broad range of life-threatening conditions, and, with GCS-100, LJPC has the most advanced galectin-3-targeting compound in development.
In connection with the acquisition, the company has also appointed Saiid Zarrabian as an independent director of the company. Also, the former members of management team at LJPC, including Deirdre Y. Gillespie, and Gail A. Sloan, have resigned.
Galectin-3 plays a significant role in the immune system’s response to cancer and tissue injury, which makes specific inhibitors of galectin-3 attractive therapeutic candidates for a wide range of life-threatening diseases such as cancer, heart failure, kidney disease, pulmonary fibrosis and liver fibrosis.
GCS-100’s continuing development as an anti-cancer and anti-fibrotic agent is backed by extensive preclinical and clinical investigation. Experimental results show that GCS-100 specifically inhibits galectin-3 in immune cells isolated from patients, confers anti-cancer activity in patients with several tumor types, exhibits effects on the immune system in patients consistent with its galectin-3 inhibitory mechanism and is safe and well-tolerated at doses that confer clinical activity.
No comments:
Post a Comment